Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13223304 | 0.87 | DGAT1 (0.34) | DGAT1NPC1 | |
| SCHEMBL67719 | 0.80 | DGAT1 (0.35) | DGAT1NPC1 | |
| SCHEMBL4837991 | 0.79 | F11 (0.38) | DGAT1NPC1 | |
| SCHEMBL6211362 | 0.79 | NPC1 (0.35) | DGAT1NPC1 | |
| SCHEMBL5213310 | 0.78 | DGAT1 (0.37) | DGAT1NPC1 | |
| SCHEMBL15459169 | 0.78 | NPC1 (0.32) | DGAT1NPC1 | |
| SCHEMBL23123528 | 0.76 | DGAT1 (0.34) | DGAT1NPC1 | |
| SCHEMBL30449989 | 0.75 | DGAT1 (0.34) | DGAT1NPC1 | |
| SCHEMBL5214265 | 0.75 | DGAT1 (0.34) | DGAT1NPC1 | |
| SCHEMBL25586533 | 0.75 | DGAT1 (0.36) | DGAT1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3829559-B1 | INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION | MERCK SHARP & DOHME LLC (US) | 2026-05-13 | — | — | EP | disclosed |
| US-12404274-B2 | Macrocycles as factor xia inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-09-02 | — | — | US | disclosed |
| US-12331044-B2 | Inhibitors of histone deacetylase useful for the treatment or prevention of HIV infection | MERCK SHARP & DOHME LLC (US) | 2025-06-17 | — | — | US | disclosed |
| US-20230058729-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2023-02-23 | — | — | US | disclosed |
| US-11136327-B2 | Macrocycles as factor XIA inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-10-05 | — | — | US | disclosed |
| US-20210276992-A1 | INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION | MERCK SHARP & DOHME CORP. (US) | 2021-09-09 | — | — | US | disclosed |
| EP-3829559-A1 | INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION | Merck Sharp & Dohme Corp. (US) | 2021-06-09 | — | — | EP | disclosed |
| EP-3786165-A1 | SYNTHETIC INTERMEDIATES FOR PRODUCING MACROCYCLES AS FACTOR XIA INHIBITORS | Bristol-Myers Squibb Company (US) | 2021-03-03 | — | — | EP | disclosed |
| EP-2534154-B1 | MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-08-05 | — | — | EP | disclosed |
| US-20200087312-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB (US) | 2020-03-19 | — | — | US | disclosed |
| WO-2020028150-A1 | INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION | MERCK SHARP & DOHME CORP. (US) | 2020-02-06 | — | — | WO | disclosed |
| US-20180022753-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-01-25 | — | — | US | disclosed |
| US-9802939-B2 | Macrocycles as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-31 | — | — | US | disclosed |
| WO-2016109706-A1 | FUSED POLYCYCLIC 2-PYRIDINONE ANTIBACTERIAL COMPOUNDS | PTC THERAPEUTICS, INC. (US) | 2016-07-07 | — | — | WO | disclosed |
| US-20150112058-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-04-23 | — | — | US | disclosed |
| US-8940720-B2 | Macrocycles as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-01-27 | — | — | US | disclosed |
| EP-2534154-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | Bristol-Myers Squibb Company (US) | 2012-12-19 | — | — | EP | disclosed |
| US-20120041190-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-02-16 | — | — | US | disclosed |
| WO-2011100401-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150112058-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F11 | DGAT1 4152/4885NPC1 2027/4885 |
| US-20120041190-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F11 | DGAT1 4152/4885NPC1 2027/4885 |
| US-20200087312-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F11 | DGAT1 4152/4885NPC1 2027/4885 |
| US-12404274-B2 | Macrocycles as factor xia inhibitors | TFPI, TFPI2, F11 | DGAT1 4152/4885NPC1 2027/4885 |
| US-12331044-B2 | Inhibitors of histone deacetylase useful for the treatment or prevention of HIV infection | HDAC1, HDAC11, HDAC10 | DGAT1 4019/4885NPC1 1079/4885 |
| US-20210276992-A1 | INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION | HDAC1, HDAC11, HDAC10 | DGAT1 4019/4885NPC1 1079/4885 |
| US-11136327-B2 | Macrocycles as factor XIA inhibitors | TFPI, TFPI2, F11 | DGAT1 4152/4885NPC1 2027/4885 |
| US-20180022753-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F11 | DGAT1 4152/4885NPC1 2027/4885 |
| US-20230058729-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F11 | DGAT1 4152/4885NPC1 2027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.